Skip to main content

Table 2 Breast milk TGF-β concentrations in the probiotic and placebo groups at 10 days and 3 months postpartum

From: Atopic dermatitis prevention in children following maternal probiotic supplementation does not appear to be mediated by breast milk TSLP or TGF-β

  Days Treatment pa
Probiotic Placebo
n Median (IQR) (pg/mL) n Median (IQR) (pg/mL)
TGF-β1 10 128 616.9 (407.5–950.4) 127 617.3 (369.7–853.9) 0.34
0.33
  90 123 438.5 (308.0–661.1) 124 417.4 (269.3–641.8) 0.27
0.23
TGF-β2 10 128 909.8 (451.6–1653.8) 127 999.4 (519.0–1517.1) 0.90
0.83
  90 123 599.6 (311.0–1055.1) 124 532.5 (285.9–1144.2) 0.76
0.69
TGF-β3 10 128 37.8 (25.3–58.7) 127 35.8 (22.9–57.2) 0.25
0.33
  90 123 29.9 (21.0–42.7) 123 30.8 (18.8–48.7) 0.95
0.86
  1. aThe upper p-value provided is from the regression analysis of the influence of probiotic ingestion on the log transformed TGF beta concentration by, whilst the lower represents the p-value calculated for the effect of treatment allocation after adjusting for maternal atopy, maternal smoking and presence of siblings